Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced its participation in key virtual investor conferences. The H.C. Wainwright Global Investment Conference is set for May 24, 2022, with a fireside chat starting at 8:30 a.m. ET. Following this, Mirum will present at the Jefferies Healthcare Conference on June 9, 2022, from 9:00-9:30 a.m. ET. The company focuses on treatments for rare liver diseases, with its approved drug LIVMARLI for Alagille syndrome and investigational treatments for various liver diseases.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences:

H.C. Wainwright Global Investment Conference
Fireside chat on May 24, 2022 starting at 8:30 a.m. ET

Jefferies Healthcare Conference
Presentation on June 9, 2022 from 9:00-9:30 a.m. ET

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006159/en/

Mirum Contacts:

Media:

Erin Murphy

media@mirumpharma.com

Investors:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

What is the date of Mirum Pharmaceuticals' participation in the H.C. Wainwright Global Investment Conference?

Mirum Pharmaceuticals will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022.

When is the Jefferies Healthcare Conference presentation for Mirum Pharmaceuticals?

The Jefferies Healthcare Conference presentation for Mirum Pharmaceuticals is scheduled for June 9, 2022, from 9:00-9:30 a.m. ET.

What is LIVMARLI and what condition does it treat?

LIVMARLI is an approved medication by Mirum Pharmaceuticals for treating cholestatic pruritus in patients with Alagille syndrome.

Is Mirum Pharmaceuticals involved in any clinical trials?

Yes, Mirum Pharmaceuticals is currently conducting clinical trials for LIVMARLI and other investigational treatments for rare liver diseases.

What is the stock symbol for Mirum Pharmaceuticals?

The stock symbol for Mirum Pharmaceuticals is MIRM.